ABSI - NASDAQ
Absci Corporation
$5.94
-6.5%Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
At a Glance
Live SnapshotAbsci Corporation Management Team
Dr. Zachariah Jonasson Ph.D.
Chief Business Officer & Chief Financial Officer
Compensation
$813,300
Dr. Andreas Busch Ph.D.
Chief Innovation Officer & Member of Scientific Advisory Board
Compensation
$1,172,058
Ms. Shelby Walker J.D.
Chief Legal Officer
Ms. Karin Wierinck
Chief People Officer
Melissa Patterson Ph.D.
Chief of Staff
Mr. Wen Sha
Chief of Staff
Mr. Sean McClain
Founder, Chief Executive Officer, President & Director
Compensation
$1,070,440
Mr. Todd Bedrick CPA
Senior Vice President & Chief Accounting Officer
Dr. Christine Lemke D.V.M., M.B.A., Ph.D.
Senior Vice President of Portfolio & Growth Strategy
Mr. Alexander Khan CPA
Vice President of Finance & Head of Investor Relations
Absci Corporation Insider Positioning
During the last 12 months, insiders have purchased $1.68M and sold $332K worth of ABSI shares, resulting in $1.35M of net buying activity.
3 Months
137.5K
429.75K
0
0.00
+430K
+$430K
3-6 Months
75.1K
205.76K
44.3K
132.33K
+73K
+$73K
6-9 Months
145.8K
430.59K
48.7K
179.30K
+251K
+$251K
9-12 Months
228.4K
612.27K
8.3K
19.88K
+592K
+$592K
Top Buyers
Pangalos Menelas N
Director
$661K
Szela Mary T
Director
$460K
Busch Andreas
Officer: Chief Innovation Officer
$381K
Van Houten Frans
Director
$149K
Bedrick Todd
Officer: Svp, Cao
$27K
Top Sellers
Mcclain Sean
Director, Officer: Chief Executive Officer
$166K
Bedrick Todd
Officer: Svp, Cao
$81K
Jonasson Zachariah
Officer: Cfo / Cbo
$74K
Busch Andreas
Officer: Chief Innovation Officer
$11K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $1.35M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider buyers vs. 4 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
SEC Filings
ABSI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | April 22, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | April 28, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 23, 2024 | April 23, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | April 28, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 26, 2022 | April 26, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.